Nanobody-TurboID Maps the CD38 Surfaceome

Cell-surface proteins rarely act in isolation. Their local organization influences signaling, adhesion, extracellular matrix interactions, and migration, yet conventional affinity purification can disrupt these spatial relationships during sample preparation. The reference study, Exploring the CD38-associated surfaceome via nanobody-targeted TurboID, addresses this problem by combining a protein-specific nanobody with the proximity-labeling enzyme TurboID.

The resulting nanobody-targeted TurboID platform, termed NBID, was used to examine the molecular neighborhood of CD38 in living cells. The work is important not because every labeled protein is necessarily a direct CD38 binding partner, but because it provides a spatially informed inventory of proteins that occupy the same local membrane environment under comparatively native conditions.

Study Background and Research Question

CD38 is a cell-surface glycoprotein with functions connected to its surrounding protein environment. Its biological effects can depend on membrane organization, adhesion complexes, and interactions with neighboring cells rather than on CD38 abundance alone. A central challenge is therefore to identify the proteins that are close to CD38 at the cell surface while preserving the organization of living cells.

The study asked whether a CD38-specific nanobody could deliver TurboID to the correct membrane neighborhood and generate a useful surfaceome profile. The authors also examined whether the CD38-associated proteins were conserved across different cell contexts, whether the neighborhood responded to NAD+ treatment, and whether candidate proteins contributed to tumor-cell migration. A further question was whether proximity labeling could resolve protein assemblies formed when tumor cells interact with endothelial cells.

Key Innovation from the Reference Study

NBID is based on a nanobody–TurboID chimera, or NTC. The nanobody supplies molecular recognition for the protein of interest, while TurboID catalyzes local biotinylation of nearby proteins. After labeling, biotinylated proteins can be enriched by affinity capture and identified by liquid chromatography–tandem mass spectrometry. This design differs from untargeted surface proteomics because the labeling enzyme is positioned through a defined recognition reagent.

A major methodological strength is the use of a compact nanobody rather than a full antibody. Nanobodies can be engineered into fusion proteins and may be more compatible with intracellular expression, controlled targeting, and proximity-labeling workflows. In this study, an EGFR-targeting NTC served as a validation system and recovered multiple proteins already associated with EGFR, supporting the ability of the platform to report biologically relevant neighborhoods.

The innovation is therefore both technical and conceptual. Technically, NBID adapts TurboID for targeted surfaceome mapping in live adherent cultures. Conceptually, it shifts the analysis from a static list of expressed proteins toward a local protein neighborhood that can include adhesion molecules, extracellular matrix regulators, lipid-raft-associated components, and signaling proteins.

Methods and Experimental Design Insights

The authors applied CD38-specific NBID in A549 lung cancer cells and THP-1 monocytic leukemia cells. The use of two cellular systems allowed the investigators to distinguish broadly recurring CD38-proximal proteins from context-dependent candidates. Following proximity labeling, proteins were captured through their biotin modification, digested with trypsin, and analyzed by LC–MS/MS. Quantitative comparisons and functional annotation were then used to identify enriched biological categories.

The workflow also included several orthogonal validation steps. Total internal reflection fluorescence microscopy, or TIRFM, was used to visualize proteins at or near the plasma membrane and to determine whether selected candidates co-clustered with CD38 on membrane protrusions. This is a useful complement to mass spectrometry because it tests spatial organization directly, although colocalization still does not establish a direct physical interaction.

The investigators tested whether NAD+ exposure altered the CD38-proximal surfaceome in A549 cells. They also performed transendothelial migration assays to connect the molecular findings with a cell behavior relevant to tumor dissemination. Finally, stable isotope labeling by amino acids in cell culture, or SILAC, was combined with NBID to study proximity relationships at the tumor–endothelial interface. This intercellular design extended the method beyond a single isolated plasma membrane.

Protocol Parameters

• Targeting reagent: Use a POI-specific nanobody–TurboID chimera and include an appropriate control construct to distinguish targeted enrichment from nonspecific proximity labeling.
• Cellular context: Perform the labeling workflow in living adherent cultures when the research question concerns native membrane organization, protrusions, or cell–cell interfaces.
• Proteomic readout: Enrich biotinylated proteins before trypsin digestion and LC–MS/MS, then interpret candidates using quantitative enrichment and gene-ontology analysis rather than treating every detection as a direct binder.
• Spatial validation: Use TIRFM or another membrane-resolved imaging method to test whether selected proteins occupy CD38-positive membrane domains.
• Functional follow-up: Pair the proximity map with a phenotype assay, such as transendothelial migration, when the objective is to connect surface organization with tumor-cell behavior.
• Intercellular analysis: Apply SILAC-based comparisons when distinguishing proteins associated with tumor–endothelial contact from proteins found in tumor cells cultured alone.

These parameters reflect the experimental logic of the reference study. They should be adapted to the nanobody, cell type, labeling chemistry, and mass-spectrometry platform used in a particular laboratory.

Core Findings and Why They Matter

CD38-specific NBID enriched proteins involved in cell adhesion, extracellular matrix organization, and lipid-raft-associated membrane domains in both A549 and THP-1 cells, according to the reference study. This result supports the view that CD38 occupies a structured membrane environment rather than functioning as an isolated surface antigen. The overlap between cell systems also suggests that some components of the CD38 neighborhood may be broadly relevant, although their abundance and functional contribution could remain cell-type dependent.

In A549 cells, Wnt-related proteins were additionally enriched. This observation expands the possible functional interpretation of CD38 proximity in a lung cancer model, but it should be understood as an association-level result. Proximity labeling can capture proteins located within the labeling range of TurboID, including members of a shared membrane domain or a multiprotein complex. It does not, by itself, demonstrate that CD38 directly activates Wnt signaling.

NAD+ treatment did not significantly change the CD38-proximal surfaceome in A549 cells. This negative result is informative because it indicates that the detected neighborhood was not readily remodeled under the tested treatment condition. It also cautions against assuming that a known biochemical connection between CD38 and NAD+ metabolism will necessarily produce a large change in the local surface proteome.

TIRFM showed that several enriched candidates co-clustered with CD38 on membrane protrusions. These observations provide imaging support for the proteomic data and focus attention on protrusion-associated membrane organization as a possible setting for CD38 function. The migration experiments further showed that CD38 contributes to A549 transendothelial migration. Together, the results connect a nanoscale surface neighborhood with a multicellular behavior involving endothelial barriers.

The SILAC-enabled intercellular experiments were particularly significant. They identified CD38-associated cadherin adhesion complexes involving CDH2 and DSG2 at the tumor–endothelial interface. Additional candidates highlighted in the study included CDH2, MRC2, CD99, CTNNB1, and DSG2, among others. These findings suggest that CD38 may participate in an adhesion network that helps organize tumor-cell contact with endothelial cells, rather than acting only as a metabolic or signaling-associated surface protein.

For researchers, the broader message is that surfaceome studies benefit from combining discovery-scale proximity labeling with microscopy and functional testing. A proteomic candidate becomes more compelling when it is spatially supported and linked to a measurable phenotype, while the phenotype itself becomes more interpretable when anchored to a defined molecular neighborhood.

Comparison with Existing Internal Articles

The internal overview Nanobody-TurboID Maps the CD38 Surfaceome emphasizes the same central workflow: targeted proximity labeling followed by proteomics, imaging, and migration assays. The reference study provides the underlying experimental rationale and a more nuanced interpretation of the results, particularly the distinction between proximity, colocalization, and direct interaction.

Compared with a conventional surface-protein catalog, the NBID study is more spatially selective. Compared with a single microscopy experiment, it offers broader molecular coverage. Its strongest contribution is the integration of these approaches around CD38 and the extension of the analysis to tumor–endothelial contact through SILAC.

Limitations and Transferability

Several limitations define how the findings should be used. First, TurboID labels proteins within a local reaction range, so the CD38-proximal proteome is not equivalent to a purified CD38 interactome. Candidate proteins may be direct partners, indirect complex members, neighboring membrane proteins, or components of the same protrusion or lipid domain. Independent biochemical or genetic experiments are needed to resolve these possibilities.

Second, the results were obtained in selected cancer and leukemia cell models. A549 and THP-1 cells differ in lineage, morphology, membrane composition, and migration behavior; therefore, the shared candidates may be robust, whereas cell-specific enrichments require validation in additional models. The response to NAD+ was also assessed in A549 cells under the reported experimental conditions and should not be generalized to all CD38-expressing systems.

Third, nanobody performance is target dependent. Binding affinity, epitope accessibility, chimera expression, membrane orientation, and TurboID activity can all influence the labeling profile. Appropriate controls, biological replicates, imaging validation, and functional perturbation are essential for separating biological signal from construct-specific effects.

Transferability is strongest for studies asking where a defined surface protein sits within a dynamic membrane environment. NBID may be useful for receptor neighborhoods, adhesion interfaces, or other surface assemblies, but each application requires a validated nanobody and a carefully matched negative-control strategy. The reference study establishes a platform and a CD38-centered biological model, not a universal map of surface interactions.

Research Support Resources

For complementary experiments that quantify cell division rather than surface proximity, researchers can use CFDA-SE (Carboxyfluorescein diacetate succinimidyl ester), SKU C3430. This intracellular esterase-activated fluorescent cell-labeling reagent is retained after conversion to CFSE and diluted with successive divisions, making it suitable for flow cytometry proliferation tracking. Depending on the model, it can support a lymphocyte proliferation assay, fibroblast proliferation monitoring, natural killer cell proliferation studies, or a bacterial proliferation assay.

Why this cross-domain matters, maturity, and limitations

CFDA-SE readouts can complement NBID-based migration or interaction studies by reporting cell division as a separate biological variable, but the dye does not measure CD38 proximity, protein interaction, or transendothelial migration directly. The two approaches should therefore be treated as complementary assays with distinct endpoints. Any combined workflow requires cell-type-specific staining optimization, viability controls, and flow-cytometry compensation rather than assuming that a proliferation profile explains the surfaceome result.